🇺🇸 FDA
Patent

US 10889834

Methods and compositions for enhancing targeted transgene integration

granted A61KA61K31/4745A61K31/7048

Quick answer

US patent 10889834 (Methods and compositions for enhancing targeted transgene integration) held by Sangamo Therapeutics, Inc. expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sangamo Therapeutics, Inc.
Grant date
Tue Jan 12 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K31/4745, A61K31/7048, A61K48/00